A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 77-84

  Lee, Jeeyun ^a   Im, Young Hyuck ^a   Cho, Eun Yoon ^a   Hong, Yong Sang ^a   Lee, Hyo Rak ^a   Kim, Hyo Song ^a   Kim, Mi Jin ^a   Kim, Kwhanmien ^a   Kang, Won Ki ^a   Park, Keunchil ^a   Shim, Young Mog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; DEATH; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; PATIENT ABANDONMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; DEOXYCYTIDINE; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 42149176013     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0577-6     Document Type: Article

References (20)

1. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053
2. Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26:2-8
3. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA (1998) Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339:1979-1984
4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
5. Enzinger PC, Ilson DH, Kelsen DP (1999) Chemotherapy in esophageal cancer. Semin Oncol 26:12-20
6. Devita VT HS, Rosenberg SA (2005) Cancer: principles and practice of oncology, 7th edn. Lippincott Williams and Wilkins, Philadelphia
7. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216-1220
8. McGavin JK, Goa KL (2001) Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 61:2309-2326
9. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr (2006) Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:29-34
10. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK (2005) Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 92:246-251
11. Viteri A, Barcelo-Galindez R, Rubio I et al (2004) Cisplatin and capecitabine as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 22:14s (Abstr#4187)
12. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893-1898
13. Kang YK, Kang WK, Shin DB et al (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC) efficacy and safety results. J Clin Oncol 24:934 (Abstr# LBA4018)
14. Lindebjerg J, Nielsen JN, Hoeffding LD, Jakobsen A (2005) Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. APMIS 113:600-602
15. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
16. Cunningham D RS, Starling N et al (2006) Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL-2 trial. J Clin Oncol 24:186 (abstr#LBA4017)
17. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C, Lordick F (2005) Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92:2129-2133
18. Jatoi A, Foster N, Johnson P, Klee G, Quevedo JF, Morton RF, Nair S, Kardinal CG, Mailliard JA (2004) Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer. A multi-institutional study from the North Central Cancer Treatment Group. Dis Esophagus 17:292-296
19. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R (2006) Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:4069-4077
20. Han JY, Hong EK, Lee SY, Yoon SM, Lee DH, Lee JS (2005) Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol 58:650-654